Alcon to Showcase Latest Innovations at AAO 2024 Annual Meeting

Alcon will unveil its latest clinical data and product innovations at the American Academy of Ophthalmology (AAO) 2024 annual meeting. Attendees, including ophthalmologists, surgical staff, researchers, and industry leaders, are invited to visit Alcon at booth #4008 for hands-on demonstrations and interactive experiences.

“The heart of Alcon remains a relentless pursuit of improving outcomes and helping patients see brilliantly,” Jim Di Filippo, Vice President and General Manager of US Surgical at Alcon, said in company news release. “Our vision extends beyond this; we are equally focused on efficiency, ensuring our innovations deliver quality and performance. From pioneering technologies like Voyager DSLT and UNIFEYE to our cloud-connected Alcon Vision Suite, we are dedicated to advancing ophthalmology and streamlining surgical workflows.”

Product Innovations: Voyager DSLT and UNIFEYE Gas Delivery

Alcon's Voyager Direct Selective Laser Trabeculoplasty (DSLT) device will be available for demonstration. Voyager DSLT, a recent addition to Alcon’s glaucoma portfolio, offers an advanced laser therapy for glaucoma, utilizing proprietary eye-tracking technology for precise, automated treatment through the limbus. Its innovative design eliminates the need for a gonio lens or manual aiming, improving both patient and physician experience, according to Alcon. This precision and ease of use make Voyager DSLT a potential first-line treatment for glaucoma care.

In addition, Alcon will introduce the UNIFEYE Gas Delivery System at AAO 2024. This handheld device integrates all gas delivery components, providing surgeons with a predictable, precise gas-to-air ratio. The streamlined setup saves time and gas by eliminating the manual attachment of gas cylinders and filters. Also debuting at the meeting is the UNIPEXY Gas Delivery System, a portable device designed for in-clinic pneumatic retinopexy. Both UNIFEYE and UNIPEXY are expected to be commercially available in 2025.

Clinical Data Presentations

Alcon will also showcase new data on its surgical products at the AAO meeting. Notable studies include:

• "Comparing the effects of two different intraocular pressure settings during routine phacoemulsification in patients with diabetic retinopathy and glaucoma" (ENHANSE) by David H. Steel, FRCOphth.
• "Evaluation of the ergonomic consequences of using NGENUITY 3D compared to the standard microscope for cataract surgery" by Everardo Hernandez-Quintela, MD.
• "Visual Performance of a Trifocal IOL in Patients with Mild Open-Angle Glaucoma Undergoing Concurrent Minimally Invasive Glaucoma Surgery" by Steven D. Vold, MD.

Additionally, pivotal data from the phase 3 COMET 2 & 3 studies on AR-15512 (acoltremon ophthalmic solution 0.003%) will be presented. This investigational drug for dry eye disease will be highlighted by David Wirta, MD, in a presentation titled “AR-15512: A Novel TRPM8 Agonist for the Treatment of the Signs and Symptoms of Dry Eye.”